查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024192

寡核苷酸合成市場（第四版）：按寡核苷酸長度、應用、類別、類型、產品和地區分類 - 預測及人工智慧 (AI) 的影響 - 高階主管和顧問指南 (2026–2030)

Oligonucleotide Synthesis Markets 4th Edition. Forecasts by Oligo Length, Application, Category, Type, Product, and Region. With Executive and Consultant Guides. 2026 to 2030. Includes Impact of Artificial Intelligence.
出版日期: | 出版商: Howe Sound Research | 英文 415 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

市場概況：

合成寡核苷酸是指利用化學或酵素法產生短鏈DNA或RNA，用於研究、診斷和治療。寡核苷酸通常由約15至200個鹼基對組成，但也可以利用其他分子生物學技術來建構較長的結構。這些合成核酸分子在現代基因組學、分子診斷、基因編輯和核酸療法中發揮著至關重要的作用。

受分子生物學、基因組醫學和生物技術進步的推動，全球合成寡核苷酸市場正經歷強勁成長，這主要得益於對客製化DNA和RNA序列需求的不斷擴大。預計到2025年，該市場規模將達到36.8億美元。以14.8%的年成長率計算，預計到2030年，該市場規模將達到73.5億美元。

這一成長主要得益於聚合酵素鏈鎖反應(PCR)、次世代定序(NGS)、基因編輯技術（如 CRISPR）、反義核酸治療藥物、 RNA干擾(RNAi)、傳訊RNA(mRNA) 技術以及合成生物學研究等領域的廣泛應用。精準醫療方法的日益普及也推動了對客製化寡核苷酸合成服務的需求。

在分子生物學和基因組學中的作用

合成寡核苷酸是分子生物學工作流程的基礎工具。 PCR引子和探針依賴短的DNA序列，這些序列經過設計，能夠與特定的基因區域結合，從而實現目標序列的擴增和檢測。寡核苷酸也用於定序樣品製備、雜合反應實驗和基因表現分析。

次世代定序技術的進步顯著增加了對用於定序接頭、索引引子和捕獲探針的客製化寡核苷酸的需求。高通量定序工作流程通常需要大量獨特的寡核苷酸序列，這進一步推動了市場的持續擴張。

基因編輯技術，例如CRISPR-Cas系統，也依賴合成寡核苷酸來建構引導RNA，從而誘導基因組修飾活性。基因編輯工具在研發和治療方法開發中日益廣泛的應用，進一步推高了對高品質合成核酸的需求。

合成寡核苷酸在合成生物學中也發揮著至關重要的作用，其中 DNA 序列被設計用於建構生物迴路和改造微生物。

治療用途

合成寡核苷酸市場中成長最快的領域之一是核酸療法。反義寡核苷酸（ASO）、小干擾RNA（siRNA）、基於微型RNA的治療方法和傳訊RNA（mRNA）療法是標靶基因表現路徑的關鍵治療方法。

基於RNA的療法因其能夠從基因層面靶向疾病機制，正吸引大量投資。寡核苷酸療法正被開發用於治療罕見遺傳疾病、癌症、心血管疾病和神經系統疾病。

為了提高治療性寡核苷酸的穩定性、結合親和性和藥物動力學特性，通常會引入硫代磷酸酯鍵、鎖定核（LNA）和胜肽核（PNA）等化學修飾。

治療性寡核苷酸的生產需要高純度和嚴格的品管，這支撐了對專業合約開發和生產組織 (CDMO) 的需求。

技術平台

傳統上，合成寡核苷酸依賴亞磷醯胺化學，即透過依序將核苷酸添加到不斷成長的DNA或RNA鏈上。自動化合成設備使得高精度合成大量寡核苷酸序列成為可能。

為了確保序列的準確性並去除合成副產物，採用高效液相層析（HPLC）和質譜等純化技術。

新型酵素DNA合成技術正被開發出來，作為傳統化學合成方法的替代方案。酶促方法在合成速度、環境友善性和產生更長DNA序列方面具有潛在優勢。

我們的自動化高通量合成平台提高了效率，縮短了客製化寡核苷酸訂單的交付週期。

合成技術與生物資訊工具的結合，可以快速設計和訂購客製化序列。

市場促進因素

多種因素促成了合成寡核苷酸合成市場的成長。

基因組研究和次世代定序的日益普及，推動了對客製化DNA序列的需求。

核酸療法的發展催生了對高品質RNA和DNA合成的需求。

PCR技術在分子診斷上的應用日益廣泛，推動了對引子和探針的持續需求。

基因編輯技術的進步增加了對嚮導RNA合成的需求。

合成生物學的研究正在推動人工DNA構建體的廣泛應用。

對個人化醫療投入的增加正在促進標靶治療方法的發展。

合成工作流程的自動化提高了可擴展性，並降低了每個鹼基的成本。

市場區隔

合成寡核苷酸合成市場可依產品類型、應用、最終用戶和地區進行細分。

按產品類型分類，DNA寡核苷酸佔最大佔有率，其次是RNA寡核苷酸，然後是用於治療目的的修飾寡核苷酸。

按應用領域分類，科學研究應用（包括PCR、定序和基因編輯工作流程）佔了大部分需求。治療應用則是一個快速成長的領域。

最終用戶包括學術研究機構、生物技術公司、製藥公司、受託研究機構和診斷測試實驗室。

北美是最大的區域市場，這得益於其強大的生物技術研究基礎設施和製藥產業。隨著基因組研究投資的增加，歐洲和亞太市場也不斷擴張。

競爭格局

合成寡核苷酸合成市場包括領先的生命科學公司、專業合成供應商和契約製造組織。

競爭取決於合成精度、交付時間、成本效益以及處理複雜修改的能力。

各公司正擴大提供將定序工具、合成服務、純化和分析檢驗相結合的整合解決方案。

合成藥物供應商與製藥公司之間的策略夥伴關係很常見，尤其在基於 RNA 的療法開發中更為突出。

與合成化學和核苷酸修飾相關的智慧財產權在建立競爭優勢方面發揮著至關重要的作用。

未來展望

隨著基因組技術和核酸療法的進步，合成寡核苷酸的市場預計將繼續擴大。

酶合成技術有望提高生產效率並減少對環境的影響。

基因編輯和合成生物學的進步可能會增加對更長、更複雜的DNA結構的需求。

合成工作流程的自動化有可能降低每個鹼基的成本並提高可擴展性。

將人工智慧工具整合到序列設計中，有可能提高合成核酸的性能。

RNA治療產品線的擴展預計將推動對高品質寡核苷酸生產的需求。

整體而言，合成寡核苷酸是基因組研究、分子診斷和精準醫療的重要基礎技術。持續的技術創新和不斷拓展的治療應用有望支撐市場持續成長。

目錄

第1章 市集指南

  • 情境分析
  • 高階主管和行銷負責人的指南
  • 投資分析師和管理顧問指南
  • 人工智慧的影響

第2章：引言與市場定義

  • 什麼是寡核苷酸合成？
  • 市場定義
  • 調查方法
  • 展望：醫療保健和體外診斷行業

第3章：寡核苷酸合成

  • 合成技術
  • 自動化
  • 寡核苷酸的類型
  • PCR引子
  • PCR檢測與試劑盒
  • 序列分析
  • DNA微陣列
  • 螢光原位雜合反應（FISH）
  • 反義寡核苷酸
  • 寡核苷酸的其他用途
  • CRISPR與基因編輯的關係

第4章 行業概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室（POLS）
    • 審計機構
    • 認證機構

第5章 市場因素

  • 成長促進因素
  • 成長阻礙因素
  • 接下來的五年

第6章：寡核苷酸合成的最新進展

第7章：主要企業概況

  • Abbott Laboratories
  • Agilent
  • Ajinomoto Bio-Pharma
  • Amyris
  • Ansa BioTechnologies
  • ATG：biosynthetics
  • ATUM
  • Azenta
  • Bayer
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Biogen
  • Biolytic Lab Performance
  • Biomatik
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Biospring
  • Bio-Synthesis
  • Biotage
  • Blue Heron Biotechnology（Eurofins Genomic）
  • Camena Bioscience
  • Cepheid（Danaher）
  • Chemgenes
  • Codexis
  • Cytena
  • Diasorin SpA
  • DNA Script
  • Enzo Biochem
  • Eurofins Scientific
  • Eurogentec（Kaneka）
  • Evonetix
  • FASMAC
  • GE Healthcare
  • Genomatica
  • Genscript Biotech
  • Glycogene Inc.
  • Hologic
  • Hongene Biotech
  • Innovassynth
  • Integrated DNA Technologies（Danaher）
  • Ionis Pharmaceuticals
  • J&J Innovative Medicine
  • Kern Systems
  • LGC Biosearch Technologies
  • Macrogen
  • Maravai LifeSciences Holdings
  • Merck & Co., Inc
  • Microsynth
  • Millipore Sigma
  • Molecular Assemblies
  • New England Biolabs, Inc.
  • Nippon Shinyaku
  • Nitto Denko（Avecia）
  • Nuclera
  • Oligo Factory
  • Panagene
  • Primerdesign（Novacyt）
  • Qiagen
  • Revvity
  • Roche Diagnostics
  • Seegene
  • Siemens Healthineers
  • Synthego
  • TAG Copenhagen A/S
  • Thermo Fisher Scientific
  • Twist Bioscience

第8章：全球寡核苷酸合成市場概覽

  • 全球市場各國概覽
  • 按寡核苷酸長度分類的全球市場規模
  • 全球市場規模（按應用領域分類）概覽
  • 全球市場規模（按產品分類）概覽
  • 全球市場規模（按類別分類）概覽
  • 全球市場規模（按類型分類）概覽

第9章：全球長度市場

  • 20歲以下
  • 21～50mer
  • 51-100mer
  • 超過100個

第10章 按應用分類的世界市場

  • 研究
  • 診斷
  • 治療
  • 數據

第11章 世界產品市場

  • 寡核苷酸
  • 測量儀器
  • 核苷
  • 其他

第12章 全球市場（依類別分類）

  • 底漆
  • 探測
  • DNA
  • RNA
  • 其他

第13章 全球市場類型

  • 標準寡核苷酸
  • 客製化寡核苷酸

第14章附錄

表格一覽

圖表清單

簡介目錄
Product Code: GENSYN 426

Market Overview:

Synthetic oligonucleotide synthesis refers to the chemical or enzymatic production of short strands of DNA or RNA designed for use in research, diagnostics, and therapeutic applications. Oligonucleotides typically consist of sequences ranging from approximately 15 to 200 nucleotides, although longer constructs may be assembled through additional molecular biology techniques. These synthetic nucleic acid molecules play essential roles in modern genomics, molecular diagnostics, gene editing, and nucleic-acid-based therapeutics.

The global Synthetic Oligonucleotide Synthesis market has experienced strong growth as advances in molecular biology, genomic medicine, and biotechnology have expanded demand for custom DNA and RNA sequences. The market size in 2025 is USD 3.68 billion. The market is growing at 14.8%. The market will reach USD 7.35 billion in 2030.

Growth is being driven by expanding applications in polymerase chain reaction (PCR), next-generation sequencing (NGS), gene editing technologies such as CRISPR, antisense therapeutics, RNA interference (RNAi), messenger RNA (mRNA) technologies, and synthetic biology research. Increasing adoption of precision medicine approaches is also supporting demand for custom oligonucleotide synthesis services.

Role in Molecular Biology and Genomics

Synthetic oligonucleotides are fundamental tools in molecular biology workflows. PCR primers and probes rely on short DNA sequences designed to bind specific genetic regions, enabling amplification and detection of target sequences. Oligonucleotides are also used in sequencing library preparation workflows, hybridization assays, and gene expression analysis.

Advances in next-generation sequencing technologies have significantly increased demand for custom oligonucleotides used in sequencing adapters, indexing primers, and capture probes. High-throughput sequencing workflows often require large numbers of unique oligonucleotide sequences, supporting continued market expansion.

Gene editing technologies such as CRISPR-Cas systems also rely on synthetic oligonucleotides to create guide RNAs that direct genome modification activity. Increasing use of gene editing tools in research and therapeutic development is creating additional demand for high-quality synthetic nucleic acids.

Synthetic oligonucleotides also play a critical role in synthetic biology, where DNA sequences are designed to construct biological circuits or engineered microorganisms.

Therapeutic Applications

One of the fastest-growing segments of the synthetic oligonucleotide synthesis market is nucleic-acid-based therapeutics. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA-based therapies, and messenger RNA (mRNA) therapeutics represent important therapeutic modalities targeting gene expression pathways.

RNA-based therapeutics have attracted significant investment due to their ability to target disease mechanisms at the genetic level. Oligonucleotide therapies are being developed for rare genetic disorders, cancer, cardiovascular disease, and neurological conditions.

Chemical modifications such as phosphorothioate linkages, locked nucleic acids (LNAs), and peptide nucleic acids (PNAs) are often incorporated into therapeutic oligonucleotides to improve stability, binding affinity, and pharmacokinetic properties.

Manufacturing therapeutic oligonucleotides requires high purity and stringent quality control, supporting demand for specialized contract development and manufacturing organizations (CDMOs).

Technology Platforms

Synthetic oligonucleotide synthesis traditionally relies on phosphoramidite chemistry, which involves sequential addition of nucleotides to a growing DNA or RNA chain. Automated synthesizers enable production of large numbers of oligonucleotide sequences with high precision.

Purification techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are used to ensure sequence accuracy and remove synthesis byproducts.

Emerging enzymatic DNA synthesis technologies are being developed as alternatives to traditional chemical synthesis methods. Enzymatic approaches may offer advantages in synthesis speed, environmental sustainability, and production of longer DNA sequences.

Automation and high-throughput synthesis platforms are improving efficiency and reducing turnaround time for custom oligonucleotide orders.

Integration of synthesis technologies with bioinformatics tools enables rapid design and ordering of custom sequences.

Market Drivers

Several factors are contributing to growth of the synthetic oligonucleotide synthesis market.

Expansion of genomics research and next-generation sequencing applications is increasing demand for custom DNA sequences.

Growth in nucleic-acid-based therapeutics is creating demand for high-quality RNA and DNA synthesis.

Increasing use of PCR-based molecular diagnostics is supporting recurring demand for primers and probes.

Advances in gene editing technologies are increasing demand for guide RNA synthesis.

Synthetic biology research is expanding use of engineered DNA constructs.

Increasing investment in personalized medicine is supporting development of targeted therapeutic approaches.

Automation of synthesis workflows is improving scalability and reducing cost per base.

Market Segmentation

The synthetic oligonucleotide synthesis market can be segmented by product type, application, end user, and geographic region.

By product type, DNA oligonucleotides represent the largest segment, followed by RNA oligonucleotides and modified oligonucleotides used in therapeutic applications.

By application, research applications represent a significant portion of demand, including PCR, sequencing, and gene editing workflows. Therapeutic applications represent a rapidly growing segment.

End users include academic research institutions, biotechnology companies, pharmaceutical companies, contract research organizations, and diagnostic laboratories.

North America represents the largest regional market due to strong biotechnology research infrastructure and pharmaceutical industry presence. Europe and Asia-Pacific markets are also expanding as investment in genomics research increases.

Competitive Landscape

The synthetic oligonucleotide synthesis market includes large life sciences companies, specialized synthesis providers, and contract manufacturing organizations.

Competition is driven by synthesis accuracy, turnaround time, cost efficiency, and ability to support complex modifications.

Companies are increasingly offering integrated solutions combining sequence design tools, synthesis services, purification, and analytical validation.

Strategic partnerships between synthesis providers and pharmaceutical companies are common, particularly in development of RNA-based therapeutics.

Intellectual property related to synthesis chemistry and nucleotide modifications plays an important role in competitive positioning.

Future Outlook

The synthetic oligonucleotide synthesis market is expected to continue expanding as genomic technologies and nucleic-acid-based therapeutics advance.

Enzymatic synthesis technologies may improve production efficiency and reduce environmental impact.

Advances in gene editing and synthetic biology may increase demand for longer and more complex DNA constructs.

Automation of synthesis workflows may reduce cost per base and increase scalability.

Integration of artificial intelligence tools into sequence design may improve performance of synthetic nucleic acids.

Expansion of RNA therapeutics pipelines is expected to drive demand for high-quality oligonucleotide manufacturing.

Overall, synthetic oligonucleotide synthesis represents a critical enabling technology for genomics research, molecular diagnostics, and precision medicine. Continued technological innovation and expanding therapeutic applications are expected to support sustained market growth.

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
    • 1.1.1 Strategic Role in Modern Biotechnology
    • 1.1.2 Manufacturing Complexity and Scale-Up Challenges
    • 1.1.3 Supply Chain Constraints and Capacity Expansion
    • 1.1.4 Regulatory Complexity for Therapeutic Applications
    • 1.1.5 Pricing Pressure and Cost Structure Challenges
    • 1.1.6 Technology Innovation and Competitive Differentiation
    • 1.1.7 Dependence on Genomics and Therapeutics Markets
    • 1.1.8 Intellectual Property and Competitive Landscape
    • 1.1.9 Geographic Market Dynamics
    • 1.1.10 Outlook and Strategic Implications
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

  • 2.1 What is Oligonucleotide Synthesis?
    • 2.1.1 The Enzyme Race
    • 2.1.2 Data Storage - The Elephant in the Room
  • 2.2 Market Definition
    • 2.2.1 Market Size
    • 2.2.2 Currency
    • 2.2.3 Years
  • 2.3 Methodology
    • 2.3.1 Methodology
    • 2.3.2 Sources
    • 2.3.3 Authors
  • 2.4 Perspective: Healthcare and the IVD Industry
    • 2.4.1 Global Healthcare Spending
    • 2.4.2 Spending on Diagnostics
    • 2.4.3 Important Role of Insurance for Diagnostics

3 Oligonucleotide Synthesis

  • 3.1 Synthesis Technology
  • 3.2 Automation
  • 3.3 Types of Oligonucleotides
  • 3.4 PCR Primers
  • 3.5 PCR Assays and Panels
  • 3.6 Sequencing
  • 3.7 DNA Microarrays
  • 3.8 Fluorescence In Situ Hybridization (FISH)
  • 3.9 Antisense Oligonucleotides
  • 3.10 Other Uses of Oligonucleotides
  • 3.11 Relationship to CRISPR and Gene Editing

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body

5 Market Factors

  • 5.1 Factors Driving Growth
    • 5.1.1 The Role of Diagnostics and the Covid Effect
    • 5.1.2 The RNA Based Vaccine
    • 5.1.3 Genomic Blizzard
    • 5.1.4 Antisense Revival
    • 5.1.5 New Applications
  • 5.2 Factors Limiting Growth
    • 5.2.1 Declining Price
    • 5.2.2 Technology Lag
    • 5.2.3 COVID Realignment
  • 5.3 The Next Five Years

6 Oligonucleotide Synthesis Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Ono Pharmaceutical to acquire antisense oligonucleotide treatment
  • 6.3 Codexis Enables Manufacturing of RNAi Therapeutics
  • 6.4 Codexis Successfully Uses Enzymatic Synthesis
  • 6.5 Oligo Factory Achieves GMP Compliance
  • 6.6 Oligonucleotide Synthesis Scaled Up
  • 6.7 Antisense Oligonucleotide Lowers Tau Tangles
  • 6.8 Ansa Biotechnologies Synthesizes Longest Oligo at 1005 Bases
  • 6.9 Agilent will double oligonucleotide capacity
  • 6.10 RNA Synthesis Technology Commercialized by EnPlusOne
  • 6.11 Quick and Automated Printing of Custom Oligos
  • 6.12 WuXi STA Opens Large-Scale Oligo Manufacturing Facility
  • 6.13 Secarna Pharmaceuticals' and Evotec Achieve Programme Designation
  • 6.14 Aligos Discontinues Development of its Antisense Oligonucleotide
  • 6.15 Seegene Obtains CE Mark for Oligo Based SARS-CoV-2 Assay
  • 6.16 Biofidelity to Launch Mutation Detection Assay
  • 6.17 Oligonucleotide Therapeutics Society Holds Meeting
  • 6.18 New Oligonucleotide Synthesis Chemistry
  • 6.19 Antisense Oligonucleotides Cross Rodents' Blood-Brain Barrier
  • 6.20 New Rapid Multiplexed PCR Assay Uses Oligo Probes
  • 6.21 MIT Devises Oligo 'File System' for DNA Data Storage
  • 6.22 Nuclera Acquires E Ink Digital Microfluidics Business
  • 6.23 Twist Bioscience Hits Milestone for DNA Data Storage
  • 6.24 Twist Bioscience, Vivlion Partner on RNA Libraries for CRISPR
  • 6.25 DNA Script Launching Benchtop Synthesizer for 'DNA on Demand'
  • 6.26 RNA Disease Dx to Develop PoC Covid Test
  • 6.27 Evonetix and Analog Devices Develop GEN3 DNA Synthesis Platform
  • 6.28 ATDBio Receives Grant for Cancer Diagnosis Project
  • 6.29 Twist Bioscience Announces Therapeutic Ab
  • 6.30 Drugmakers boost oligo capacity amid Covid-19
  • 6.31 Aligos Therapeutics in Study of Oligo Candidate
  • 6.32 DNA Script Raises $89M for SYNTAX Launch
  • 6.33 Codexis & Molecular Assemblies Partner for DNA Synthesis
  • 6.34 NuProbe Licenses Oligo Technology from Rice
  • 6.35 Genome editing with Cas9-oligo conjugates
  • 6.36 OliX Pharma and AM Chemicals Partner for RNA Synthesis Support
  • 6.37 Twist Bio To End Trade Secrets Suit
  • 6.38 DNA Script, partners get grant for data storage
  • 6.39 Xi's STA unit opens oligonucleotide plant

7 Profiles of Key Companies

  • 7.1 Abbott Laboratories
  • 7.2 Agilent
  • 7.3 Ajinomoto Bio-Pharma
  • 7.4 Amyris
  • 7.5 Ansa BioTechnologies
  • 7.6 ATG:biosynthetics
  • 7.7 ATUM
  • 7.8 Azenta
  • 7.9 Bayer
  • 7.10 Beckman Coulter Diagnostics (Danaher)
  • 7.11 Becton, Dickinson and Company
  • 7.12 Biogen
  • 7.13 Biolytic Lab Performance
  • 7.14 Biomatik
  • 7.15 bioMerieux Diagnostics
  • 7.16 Bioneer Corporation
  • 7.17 Bio-Rad Laboratories, Inc.
  • 7.18 Biospring
  • 7.19 Bio-Synthesis
  • 7.20 Biotage
  • 7.21 Blue Heron Biotechnology (Eurofins Genomic)
  • 7.22 Camena Bioscience
  • 7.23 Cepheid (Danaher)
  • 7.24 Chemgenes
  • 7.25 Codexis
  • 7.26 Cytena
  • 7.27 Diasorin S.p.A.
  • 7.28 DNA Script
  • 7.29 Enzo Biochem
  • 7.30 Eurofins Scientific
  • 7.31 Eurogentec (Kaneka)
  • 7.32 Evonetix
  • 7.33 FASMAC
  • 7.34 GE Healthcare
  • 7.35 Genomatica
  • 7.36 Genscript Biotech
  • 7.37 Glycogene Inc.
  • 7.38 Hologic
  • 7.39 Hongene Biotech
  • 7.40 Innovassynth
  • 7.41 Integrated DNA Technologies (Danaher)
  • 7.42 Ionis Pharmaceuticals
  • 7.43 J&J Innovative Medicine
  • 7.44 Kern Systems
  • 7.45 LGC Biosearch Technologies
  • 7.46 Macrogen
  • 7.47 Maravai LifeSciences Holdings
  • 7.48 Merck & Co., Inc
  • 7.49 Microsynth
  • 7.50 Millipore Sigma
  • 7.51 Molecular Assemblies
  • 7.52 New England Biolabs, Inc.
  • 7.53 Nippon Shinyaku
  • 7.54 Nitto Denko (Avecia)
  • 7.55 Nuclera
  • 7.56 Oligo Factory
  • 7.57 Panagene
  • 7.58 Primerdesign (Novacyt)
  • 7.59 Qiagen
  • 7.60 Revvity
  • 7.61 Roche Diagnostics
  • 7.62 Seegene
  • 7.63 Siemens Healthineers
  • 7.64 Synthego
  • 7.65 TAG Copenhagen A/S
  • 7.66 Thermo Fisher Scientific
  • 7.67 Twist Bioscience

8 Oligonucleotide Synthesis Global Market Overview

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market Size by Length - Overview
    • 8.2.1 Table - Global Market by Length
    • 8.2.2 Chart - Global Market by Length - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Length - Base Year
    • 8.2.4 Chart - Global Market by Length - Final Year
    • 8.2.5 Chart - Global Market by Length - Share by Year
    • 8.2.6 Chart - Global Market by Length - Segment Growth
  • 8.3 Global Market Size by Application - Overview
    • 8.3.1 Table - Global Market by Application
    • 8.3.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Application - Base Year
    • 8.3.4 Chart - Global Market by Application - Final Year
    • 8.3.5 Chart - Global Market by Application - Share by Year
    • 8.3.6 Chart - Global Market by Application - Segment Growth
  • 8.4 Global Market Size by Product - Overview
    • 8.4.1 Table - Global Market by Product
    • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Product - Base Year
    • 8.4.4 Chart - Global Market by Product - Final Year
    • 8.4.5 Chart - Global Market by Product - Share by Year
    • 8.4.6 Chart - Global Market by Product - Segment Growth
  • 8.5 Global Market Size by Category - Overview
    • 8.5.1 Table - Global Market by Category
    • 8.5.2 Chart - Global Market by Category - Base/Final Year Comparison
    • 8.5.3 Chart - Global Market by Category - Base Year
    • 8.5.4 Chart - Global Market by Category - Final Year
    • 8.5.5 Chart - Global Market by Category - Share by Year
    • 8.5.6 Chart - Global Market by Category - Segment Growth
  • 8.6 Global Market Size by Type - Overview
    • 8.6.1 Table - Global Market by Type
    • 8.6.2 Chart - Global Market by Type - Base/Final Year Comparison
    • 8.6.3 Chart - Global Market by Type - Base Year
    • 8.6.4 Chart - Global Market by Type - Final Year
    • 8.6.5 Chart - Global Market by Type - Share by Year
    • 8.6.6 Chart - Global Market by Type - Segment Growth

9 Global Market by Length

  • 9.1 Less than 20 mer Market
    • 9.1.1 Table - Less than 20 mer Market by Country
    • 9.1.2 Chart - Less than 20 mer Market Segment Growth
  • 9.2 21-50 mer Market
    • 9.2.1 Table - 21-50 mer Market by Country
    • 9.2.2 Chart - 21-50 mer Market Segment Growth
  • 9.3 51-100 mer Market
    • 9.3.1 Table - 51-100 mer Market by Country
    • 9.3.2 Chart - 51-100 mer Market Segment Growth
  • 9.4 Greater than 100 mer Market
    • 9.4.1 Table - Greater than 100 mer Market by Country
    • 9.4.2 Chart - Greater than 100 mer Market Segment Growth

10 Global Market by Application

  • 10.1 Research Market
    • 10.1.1 Table - Research Market by Country
    • 10.1.2 Chart - Research Market Segment Growth
  • 10.2 Diagnostics Market
    • 10.2.1 Table - Diagnostics Market by Country
    • 10.2.2 Chart - Diagnostics Market Segment Growth
  • 10.3 Therapeutics Market
    • 10.3.1 Table - Therapeutics Market by Country
    • 10.3.2 Chart - Therapeutics Market Segment Growth
  • 10.4 Data Market
    • 10.4.1 Table - Data Market by Country
    • 10.4.2 Chart - Data Market Segment Growth

11 Global Market by Product

  • 11.1 Oligonucleotides Market
    • 11.1.1 Table - Oligonucleotides Market by Country
    • 11.1.2 Chart - Oligonucleotides Market Segment Growth
  • 11.2 Instruments Market
    • 11.2.1 Table - Instruments Market by Country
    • 11.2.2 Chart - Instruments Market Segment Growth
  • 11.3 Nucleosides Market
    • 11.3.1 Table - Nucleosides Market by Country
    • 11.3.2 Chart - Nucleosides Market Segment Growth
  • 11.4 Other Reagents Market
    • 11.4.1 Table - Other Reagents Market by Country
    • 11.4.2 Chart - Other Reagents Market Segment Growth

12 Global Market by Category

  • 12.1 Primer Market
    • 12.1.1 Table - Primer Market by Country
    • 12.1.2 Chart - Primer Market Segment Growth
  • 12.2 Probe Market
    • 12.2.1 Table - Probe Market by Country
    • 12.2.2 Chart - Probe Market Segment Growth
  • 12.3 DNA Market
    • 12.3.1 Table - DNA Market by Country
    • 12.3.2 Chart - DNA Market Segment Growth
  • 12.4 RNA Market
    • 12.4.1 Table - RNA Market by Country
    • 12.4.2 Chart - RNA Market Segment Growth
  • 12.5 Other Nucleic Acid Market
    • 12.5.1 Table - Other Nucleic Acid Market by Country
    • 12.5.2 Chart - Other Nucleic Acid Market Segment Growth

13 Global Market by Type

  • 13.1 Standard Oligonucleotides Market
    • 13.1.1 Table - Standard Oligonucleotides Market by Country
    • 13.1.2 Chart - Standard Oligonucleotides Market Segment Growth
  • 13.2 Custom Oligonucleotides Market
    • 13.2.1 Table - Custom Oligonucleotides Market by Country
    • 13.2.2 Chart - Custom Oligonucleotides Market Segment Growth

14 Appendices

  • 14.1 Typical Oligo Synthesis Price Lists
  • 14.2 Medicare Clinical Lab Fee Schedule
  • 14.3 Drug Approvals by Molecule Type - A Seven Year View
  • 14.4 Growth of Approved IVD Test Menu
  • 14.5 Growth of Approved Average IVD Test Fee
  • 14.6 Share of Pharma R&D by Country

Table of Tables

  • Table 1 Companies Formed to Exploit Enzyme Synthesis
  • Table 2 Market Players by Type
  • Table 3 Five Factors Driving Growth
  • Table 4 Three Factors Limiting Growth
  • Table 5 Global Market by Country/Region
  • Table 6 Global Market by Length
  • Table 7 Global Market by Application
  • Table 8 Global Market by Product
  • Table 9 Global Market by Category
  • Table 10 Global Market by Type
  • Table 11 Less than20 mer Market by Country
  • Table 12 21-50 mer Market by Country
  • Table 13 51-100 mer Market by Country
  • Table 14 Greater than 100 mer Market by Country
  • Table 15 Research Market by Country
  • Table 16 Diagnostics Market by Country
  • Table 17 Therapeutics Market by Country
  • Table 18 Data Market by Country
  • Table 19 Oligonucleotides Market by Country
  • Table 20 Instruments Market by Country
  • Table 21 Nucleosides Market by Country
  • Table 22 Other Reagents Market by Country
  • Table 23 Primer Market by Country
  • Table 24 Probe Market by Country
  • Table 25 DNA Market by Country
  • Table 26 RNA Market by Country
  • Table 27 Other Nucleic Acid Market by Country
  • Table 28 Standard Oligonucleotides Market by Country
  • Table 29 Custom Oligonucleotides Market by Country
  • Table 30 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Health Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 Phosphoramidites Structure
  • Figure 4 DNA/Oligonucleotide Synthetic Cycle
  • Figure 5 The Road to Diagnostics
  • Figure 6 Growth rates of Oligionucleotide Synthesis by Application
  • Figure 7 Market Size by Country
  • Figure 8 Global Market by Length - Base vs. Final Year
  • Figure 9 Length Market Base Year
  • Figure 10 Length Market Final Year
  • Figure 11 Length Share by Year
  • Figure 12 Length Segment Growth
  • Figure 13 Global Market by Application - Base vs. Final Year
  • Figure 14 Application Market Base Year
  • Figure 15 Application Market Final Year
  • Figure 16 Application Share by Year
  • Figure 17 Application Segment Growth
  • Figure 18 Global Market by Product - Base vs. Final Year
  • Figure 19 Product Market Base Year
  • Figure 20 Product Market Final Year
  • Figure 21 Product Share by Year
  • Figure 22 Product Segment Growth
  • Figure 23 Global Market by Category - Base vs. Final Year
  • Figure 24 Category Market Base Year
  • Figure 25 Category Market Final Year
  • Figure 26 Category Share by Year
  • Figure 27 Category Segment Growth
  • Figure 28 Global Market by Type - Base vs. Final Year
  • Figure 29 Type Market Base Year
  • Figure 30 Type Market Final Year
  • Figure 31 Type Share by Year
  • Figure 32 Type Segment Growth
  • Figure 33 Chart - Less than20 mer Market Growth
  • Figure 34 Chart 21-50 mer Market Growth
  • Figure 35 Chart - 51-100 mer Market Growth
  • Figure 36 Chart - Greater than 100 mer Market Growth
  • Figure 37 Chart Research Market Growth
  • Figure 38 Chart - Diagnostics Market Growth
  • Figure 39 Chart - Therapeutics market Growth
  • Figure 40 Chart - Data Market Growth
  • Figure 41 Chart Oligonucleotides Market Growth
  • Figure 42 Chart - Instruments Market Growth
  • Figure 43 Chart - Nucleosides Market Growth
  • Figure 44 Chart - Other Reagents Market Growth
  • Figure 45 Chart Primer Market Growth
  • Figure 46 Chart - Probe Market Growth
  • Figure 47 Chart - DNA Market Growth
  • Figure 48 Chart - RNA Market Growth
  • Figure 49 Chart - Other Nucleic Acid Market Growth
  • Figure 50 Chart Standard Oligonucleotides Market Growth
  • Figure 51 Chart - Custom Oligonucleotides Market Growth
  • Figure 52 Eurofins Price List
  • Figure 53 Hokkaido System Science Co. Price List
  • Figure 54 Biobasic Price List
  • Figure 55 Seven Years of FDA Approvals
  • Figure 56 IVD Test Menu Growth
  • Figure 57 IVD Test Average Fees - A Ten Year View
  • Figure 58 Share of Pharma R&D by Country